MedPath

Comparison of Voglibose and Acarbose on incretin secretion and postprandial metabolic parameters in type 2 diabetes

Not Applicable
Recruiting
Conditions
type 2 diabetes patients
Registration Number
JPRN-UMIN000003142
Lead Sponsor
Toyama Prefectural Central Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Previous use of alpha-glucosidase inhibitor, DPP-4 inhibitor, GLP-1 analog within 3 months 2)Severe ketosis, diabetic coma or diabetic precoma 3)Severe hepatic dysfunction or severe kidney dysfunction 4)Severe infection or serious trauma, perioperative patients or severe injury 5)Hypersensitivity to any ingredient of Voglibose or Acarbose 6)Severe neuropathy 7)Current treatment with steroid 8)Patients judged by the investigator to be ineligible for some other reason

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath